Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Debt to Equity: 2009-2025

Historic Debt to Equity for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to $1.05.

  • Aytu Biopharma's Debt to Equity rose 121.72% to $1.09 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.40, marking a year-over-year increase of 71.67%. This contributed to the annual value of $1.05 for FY2025, which is 119.75% up from last year.
  • Aytu Biopharma's Debt to Equity amounted to $1.05 in FY2025, which was up 119.75% from $0.48 recorded in FY2024.
  • Aytu Biopharma's 5-year Debt to Equity high stood at $1.05 for FY2025, and its period low was $0.12 during FY2021.
  • Over the past 3 years, Aytu Biopharma's median Debt to Equity value was $0.48 (recorded in 2024), while the average stood at $0.65.
  • Its Debt to Equity has fluctuated over the past 5 years, first surged by 1,084.98% in 2021, then dropped by 1.28% in 2023.
  • Aytu Biopharma's Debt to Equity (MRY) stood at $0.12 in 2021, then skyrocketed by 233.41% to $0.41 in 2022, then grew by 1.28% to $0.41 in 2023, then grew by 15.79% to $0.48 in 2024, then skyrocketed by 119.75% to $1.05 in 2025.
  • Its Debt to Equity was $1.05 in FY2025, compared to $0.48 in FY2024 and $0.41 in FY2023.